title: Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand.
abstract: To control the devastating group B meningococcal epidemic in New Zealand a strain-specific OMV vaccine (MeNZB) was extensively tested before vaccination of >1,000,000 people under 20 years. After the three-dose course 75% of 6-8-month-old infants and 16-24-month-old toddlers showed four-fold increases in bactericidal antibodies. In 6-10-week-old infants a fourth dose was needed to obtain similar results. After primary vaccination, the antibody titre decline was most pronounced among the youngest but both young infants and toddlers showed a clear booster response to a fourth dose. MeNZB was safe and well tolerated. The comprehensive post-licensure safety surveillance revealed no safety concerns.
authors.affiliation: Novartis Vaccines and Diagnostics S.r.l., Via Fiorentina 1, 53100 Siena, Italy. philipp.oster@novartis.com
authors.forename: P
authors.initials: P
authors.lastname: Oster
authors.forename: J
authors.initials: J
authors.lastname: O'Hallahan
authors.forename: I
authors.initials: I
authors.lastname: Aaberge
authors.forename: S
authors.initials: S
authors.lastname: Tilman
authors.forename: E
authors.initials: E
authors.lastname: Ypma
authors.forename: D
authors.initials: D
authors.lastname: Martin
mesh_terms: D000907:Antibodies, Bacterial / Q000097:blood; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D008589:Meningococcal Infections / Q000276:immunology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology*; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology*; D009520:New Zealand; D004364:Pharmaceutical Preparations; D012449:Safety
chemical_list: D000907:Antibodies, Bacterial; D022401:Meningococcal Vaccines; D004364:Pharmaceutical Preparations